CoChat

A Randomized, Double-Blind, Placebo-Controlled Trial: The Efficacy of Multispecies Probiotic Supplementation in Alleviating Symptoms of Irritable Bowel Syndrome Associated with Constipation

Open access
Mezzasalma, Valerio, Manfrini, Enrico, Ferri, Emanuele, Sandionigi, Anna, La Ferla, Barbara, Schiano, Irene, Michelotti, Angela, Nobile, Vincenzo, Labra, Massimo, Di Gennaro, Patrizia · 2016 · BioMed Research International

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Abstract

Background and Aim. The efficacy of supplementation treatment with two multispecies probiotic formulates on subjects diagnosed with IBS-C and the assessment of their gut microbiota were investigated.Methods. A randomized, double-blind, three-arm parallel group trial was carried out on 150 IBS-C subjects divided into three groups (F_1, F_2, and F_3). Each group received a daily oral administration of probiotic mixtures (for 60 days) F_1 or F_2 or placebo F_3, respectively. Fecal microbiological analyses were performed by species-specific qPCR to assess the different amount of probiotics.Results. The percentage of responders for each symptom was higher in the probiotic groups when compared to placebo group during the treatment period (t60) and was maintained quite similar during the follow-up period (t90). Fecal analysis demonstrated that probiotics of the formulations increased during the times of treatment only in fecal DNA from subjects treated with F_1 and F_2 and not with F_3, and the same level was maintained during the follow-up period.Conclusions. Multispecies probiotic supplementations are effective in IBS-C subjects and induce a different assessment in the composition of intestinal microbiota. This clinical study is registered with the clinical study registration number ISRCTN15032219.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1155/2016/4740907

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Study flow and schedule of assessment chart.
Figure 1 Study flow and schedule of assessment chart.CC BY · PubMed Central
Figure 2 Disposition of the subjects of the study.
Figure 2 Disposition of the subjects of the study.CC BY · PubMed Central
Figure 3 Percentage of responders to IBS-C related symptom during the treatment period (t60, days) with probiotic formulations F_1 and F_2. The Responders was defined as the subject reporting a decrease of symptoms of at least 30% compared to the basal condition for at least 50% of the intervention time. Bloating, abdominal pain, constipation, abdominal cramps, and flatulence symptoms were assessed on a numbering scale from 0 to 10 for each item subjects scored. Data are mean ± SE. Upon the square brackets are reported the intergroups F_1 and F_2 (versus placebo F_3) statistical analysis (∗∗∗ P < 0.001). The intergroups F_1 versus F_2 statistical analysis (∗∗ P < 0.01) is also reported.
Figure 3 Percentage of responders to IBS-C related symptom during the treatment period (t60, days) with probiotic formulations F_1 and F_2. The Responders was defined as the subject reporting a decrease of symptoms of at least 30% compared to the basal condition for at least 50% of the intervention time. Bloating, abdominal pain, constipation, abdominal cramps, and flatulence symptoms were assessed on a numbering scale from 0 to 10 for each item subjects scored. Data are mean ± SE. Upon the square brackets are reported the intergroups F_1 and F_2 (versus placebo F_3) statistical analysis (∗∗∗ P < 0.001). The intergroups F_1 versus F_2 statistical analysis (∗∗ P < 0.01) is also reported.CC BY · PubMed Central
Figure 4 Percentage of responders to IBS-C related symptom at the follow-up period, that is, 30 days after the last product intake (t90, days) of probiotic formulations F_1 and F_2. The Responders was defined as the subject reporting a decrease of symptoms of at least 30% compared to the basal condition for at least 50% of the intervention time. Bloating, abdominal pain, constipation, abdominal cramps, and flatulence symptoms were assessed on a numbering scale from 0 to 10 for each item subjects scored. Data are mean ± SE. Upon the square brackets are reported the intergroups F_1 and F_2 (versus placebo F_3) statistical analysis (∗∗∗ P < 0.001). The intergroups F_1 versus F_2 statistical analysis (∗∗ P < 0.01) is also reported.
Figure 4 Percentage of responders to IBS-C related symptom at the follow-up period, that is, 30 days after the last product intake (t90, days) of probiotic formulations F_1 and F_2. The Responders was defined as the subject reporting a decrease of symptoms of at least 30% compared to the basal condition for at least 50% of the intervention time. Bloating, abdominal pain, constipation, abdominal cramps, and flatulence symptoms were assessed on a numbering scale from 0 to 10 for each item subjects scored. Data are mean ± SE. Upon the square brackets are reported the intergroups F_1 and F_2 (versus placebo F_3) statistical analysis (∗∗∗ P < 0.001). The intergroups F_1 versus F_2 statistical analysis (∗∗ P < 0.01) is also reported.CC BY · PubMed Central
Figure 5 Ratio of probiotics of formulations (F_1 and F_2, versus F_3) by qPCR of species-specific sequences at the different times of treatment versus the amount at the baseline time point, expressed as bacterial counts. Upon the bars is reported the statistical analysis between treatments (∗∗∗ P < 0.001).
Figure 5 Ratio of probiotics of formulations (F_1 and F_2, versus F_3) by qPCR of species-specific sequences at the different times of treatment versus the amount at the baseline time point, expressed as bacterial counts. Upon the bars is reported the statistical analysis between treatments (∗∗∗ P < 0.001).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Research works printed but not linked: 2

  1. 2011, Annali Italiani di Chirurgia, 82, 361
  2. 2013, PloS ONE, 8

Cited by

Metadata

Authors
Mezzasalma, V., Manfrini, E., Ferri, E., Sandionigi, A., La Ferla, B., Schiano, I., Michelotti, A., Nobile, V., Labra, M., & Di Gennaro, P.
Affiliations
  • University of Milano-Bicocca (IT)
  • Department of Biotechnology and Biosciences, University of Milano-Bicocca, Piazza della Scienza 2, 20126 Milan, Italy
  • Farcoderm Srl., Via Angelini 21, San Martino Siccomario, 27028 Pavia, Italy
Venue
BioMed Research International
Publisher
Wiley
Published
2016
Volume
2016
Pages
1-10
ISSN
  • 1110-7243 (ISSN-L)
  • 2314-6133
  • 2314-6141
OpenAlex
W2510462781
Cited by
81
References
28
Citations by year
2026: 4 · 2025: 4 · 2024: 10 · 2023: 17 · 2022: 15 · 2021: 8 · 2020: 7 · 2019: 10 · 2018: 3 · 2017: 3
FWCI
5.84
Type
journal article
Language
en
Open access
Locations
  • BioMed Research International (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • BOA (University of Milano-Bicocca) (submittedVersion, other-oa)
Funders
Probioplus4Food (30221122)
Topics
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
Keywords
irritable bowel syndrome with constipation, multispecies probiotics, probiotic supplementation, gut microbiota, fecal microbiota, symptom relief
MeSH terms
Adolescent, Adult, Aged, Constipation, Double-Blind Method, Female, Follow-Up Studies, Humans, Male, Middle Aged, Dietary Supplements, Probiotics, Irritable Bowel Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.